
uniQure (QURE) Stock Forecast & Price Target
uniQure (QURE) Analyst Ratings
Bulls say
uniQure NV has reported an increase in SG&A expenses to $19.4 million from $11.6 million year-over-year, indicating a commitment to advancing its operational capabilities as it develops gene therapies for conditions such as Huntington's disease and cardiovascular diseases. Management maintains strong confidence in the AMT-130 data, which are considered exceptionally robust, and underscores the program's strong support within the scientific community, suggesting that regulatory challenges are more process-related than indicative of data quality. Furthermore, a favorable risk-benefit profile for AMT-130, combined with recent positive developments in ongoing trials for MTLE, underscores uniQure's pipeline potential and positions the company for future growth as it navigates the gene therapy market landscape.
Bears say
uniQure NV faces significant challenges that contribute to a negative outlook for its stock, primarily due to regulatory uncertainty surrounding its lead product AMT-130 and the subsequent withdrawal of previously indicated timelines for its Biologics License Application (BLA). The company has no revenue-generating products yet, leading to ongoing financial losses since its inception, which raises concerns regarding its long-term viability. Additionally, increasing market competition for gene therapies targeting similar indications may further constrain uniQure’s market penetration and affect potential pricing strategies.
This aggregate rating is based on analysts' research of uniQure and is not a guaranteed prediction by Public.com or investment advice.
uniQure (QURE) Analyst Forecast & Price Prediction
Start investing in uniQure (QURE)
Order type
Buy in
Order amount
Est. shares
0 shares